An optogenetic approach in epilepsy.
Kokaia, Merab LU ; Andersson, My LU
and Ledri, Marco
LU
(2013)
In Neuropharmacology
69(Jun 12).
p.89-95
- Abstract
- Optogenetic tools comprise a variety of different light-sensitive proteins from single-cell organisms that can be expressed in mammalian neurons and effectively control their excitability. Two main classes of optogenetic tools allow to either depolarize or hyperpolarize, and respectively generate or inhibit action potentials in selective populations of neurons. This opens unprecedented possibilities for delineating the role of certain neuronal populations in brain processing and diseases. Moreover, optogenetics may be considered for developing potential treatment strategies for brain diseases, particularly for excitability disorders such as epilepsy. Expression of the inhibitory halorhodopsin NpHR in hippocampal principal cells has been... (More)
- Optogenetic tools comprise a variety of different light-sensitive proteins from single-cell organisms that can be expressed in mammalian neurons and effectively control their excitability. Two main classes of optogenetic tools allow to either depolarize or hyperpolarize, and respectively generate or inhibit action potentials in selective populations of neurons. This opens unprecedented possibilities for delineating the role of certain neuronal populations in brain processing and diseases. Moreover, optogenetics may be considered for developing potential treatment strategies for brain diseases, particularly for excitability disorders such as epilepsy. Expression of the inhibitory halorhodopsin NpHR in hippocampal principal cells has been recently used as a tool to effectively control chemically and electrically induced epileptiform activity in slice preparations, and to reduce in vivo spiking induced by tetanus toxin injection in the motor cortex. In this review we give a comprehensive summary of what has been achieved so far in the field of epilepsy using optogenetics, and discuss some of the possible strategies that could be envisaged in the future. We also point out some of the challenges and pitfalls in relation to possible outcomes of using optogenetics for controlling network excitability, and associated brain diseases. This article is part of a Special Issue entitled 'Epilepsy'. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2859391
- author
- Kokaia, Merab
LU
; Andersson, My
LU
and Ledri, Marco
LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Neuropharmacology
- volume
- 69
- issue
- Jun 12
- pages
- 89 - 95
- publisher
- Elsevier
- external identifiers
-
- wos:000317883000011
- pmid:22698957
- scopus:84875246029
- pmid:22698957
- ISSN
- 1873-7064
- DOI
- 10.1016/j.neuropharm.2012.05.049
- language
- English
- LU publication?
- yes
- id
- 254f883c-4f2f-4dea-811e-a3bd8397ceef (old id 2859391)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/22698957?dopt=Abstract
- date added to LUP
- 2016-04-01 10:42:44
- date last changed
- 2023-10-26 17:25:38
@article{254f883c-4f2f-4dea-811e-a3bd8397ceef,
abstract = {{Optogenetic tools comprise a variety of different light-sensitive proteins from single-cell organisms that can be expressed in mammalian neurons and effectively control their excitability. Two main classes of optogenetic tools allow to either depolarize or hyperpolarize, and respectively generate or inhibit action potentials in selective populations of neurons. This opens unprecedented possibilities for delineating the role of certain neuronal populations in brain processing and diseases. Moreover, optogenetics may be considered for developing potential treatment strategies for brain diseases, particularly for excitability disorders such as epilepsy. Expression of the inhibitory halorhodopsin NpHR in hippocampal principal cells has been recently used as a tool to effectively control chemically and electrically induced epileptiform activity in slice preparations, and to reduce in vivo spiking induced by tetanus toxin injection in the motor cortex. In this review we give a comprehensive summary of what has been achieved so far in the field of epilepsy using optogenetics, and discuss some of the possible strategies that could be envisaged in the future. We also point out some of the challenges and pitfalls in relation to possible outcomes of using optogenetics for controlling network excitability, and associated brain diseases. This article is part of a Special Issue entitled 'Epilepsy'.}},
author = {{Kokaia, Merab and Andersson, My and Ledri, Marco}},
issn = {{1873-7064}},
language = {{eng}},
number = {{Jun 12}},
pages = {{89--95}},
publisher = {{Elsevier}},
series = {{Neuropharmacology}},
title = {{An optogenetic approach in epilepsy.}},
url = {{http://dx.doi.org/10.1016/j.neuropharm.2012.05.049}},
doi = {{10.1016/j.neuropharm.2012.05.049}},
volume = {{69}},
year = {{2013}},
}